Delivery of oligonucleotides with lipid nanoparticles.

[1]  R. Mohammad,et al.  Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide , 2014, Cancer Chemotherapy and Pharmacology.

[2]  Fan Wang,et al.  Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. , 2014, Biochemical and biophysical research communications.

[3]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[4]  Chih-Kuang Chen,et al.  Overcoming nonviral gene delivery barriers: perspective and future. , 2013, Molecular pharmaceutics.

[5]  A. Griveau,et al.  Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. , 2013, International journal of pharmaceutics.

[6]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  H. Harashima,et al.  A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Robert Langer,et al.  Microfluidic technologies for accelerating the clinical translation of nanoparticles. , 2012, Nature nanotechnology.

[9]  A. Befus,et al.  The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases , 2012, BioDrugs.

[10]  A. Siddiqui,et al.  Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES). , 2012, International journal of pharmaceutics.

[11]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[12]  Wenling Zheng,et al.  Anti‐miR‐155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis , 2012, Cell biology international.

[13]  K. Kono,et al.  Effect of unsaturated alkyl chains on transfection activity of poly(amidoamine) dendron-bearing lipids. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  H. Uludaǧ,et al.  Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression , 2012, Journal of drug targeting.

[15]  I. Donatelli,et al.  Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. , 2011, Antiviral research.

[16]  R. Ray,et al.  Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. , 2011, Genes & cancer.

[17]  Chenguang Zhou,et al.  A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery. , 2011, Molecular pharmaceutics.

[18]  L. J. Lee,et al.  Microfluidic assembly of lipid-based oligonucleotide nanoparticles. , 2011, Anticancer research.

[19]  Chad A Mirkin,et al.  Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. , 2011, Nano letters.

[20]  D. Levorse,et al.  Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[21]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[23]  T. Racie,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[24]  Yan-Fei Wang,et al.  [Inhibition of hepatitis B virus (HBV) replication using antisense LNA targeting to both S and C genes in HBV]. , 2009, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[25]  U. Klotz,et al.  Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA. , 2009, Journal of pharmaceutical sciences.

[26]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  D. Nosi,et al.  Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro , 2009, Archives of Virology.

[28]  Y. T. Ko,et al.  Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[29]  G. De Rosa,et al.  Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  J. Benoit,et al.  Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. , 2008, Biomaterials.

[31]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[32]  S. Pun,et al.  Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons , 2008, The journal of gene medicine.

[33]  P. Cullis,et al.  Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. , 2007, International immunopharmacology.

[34]  A. Salazar,et al.  Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. , 2007, Vaccine.

[35]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[36]  Leaf Huang,et al.  Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. , 2006, Molecular pharmaceutics.

[37]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[38]  N. Caplen,et al.  Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo , 2006, Respiratory research.

[39]  Ying K. Tam,et al.  Methods for the preparation of protein-oligonucleotide-lipid constructs. , 2006, Bioconjugate chemistry.

[40]  K. Braeckmans,et al.  Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[41]  A. Zimmer,et al.  Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  N. Christensen,et al.  Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA , 2004, Gene Therapy.

[43]  T. Allen,et al.  Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.

[44]  Y. Barenholz,et al.  Nanostructure of cationic lipid-oligonucleotide complexes. , 2004, Biophysical journal.

[45]  X. Jiao,et al.  Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. , 2004, The Journal of general virology.

[46]  W. Ahn,et al.  CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model , 2004, Immunology.

[47]  J. Lifson,et al.  CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques , 2004, AIDS.

[48]  A. Krieg.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides , 2004, Current oncology reports.

[49]  G. Prince,et al.  Immunoprotective Activity and Safety of a RespiratorySyncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with aCpG OligodeoxynucleotideAdjuvant , 2003, Journal of Virology.

[50]  D. Ribatti,et al.  Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  C Russell Middaugh,et al.  Barriers to nonviral gene delivery. , 2003, Journal of pharmaceutical sciences.

[52]  J. Holmgren,et al.  A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection , 2003, Journal of Virology.

[53]  J. Mohler,et al.  Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents* , 2002, The Journal of Biological Chemistry.

[54]  Vladimir P Torchilin,et al.  Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. , 2002, Cancer research.

[55]  A. Dritschilo,et al.  Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  B. Pitt,et al.  Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. , 2002, Bioconjugate chemistry.

[57]  I. Zuhorn,et al.  On the Mechanism of Cationic Amphiphile-mediated Transfection. To Fuse or not to Fuse: Is that the Question? , 2002, The Journal of Membrane Biology.

[58]  U. Massing,et al.  Combinatorial Synthesis of New Cationic Lipids and High‐Throughput Screening of Their Transfection Properties , 2002, Chembiochem : a European journal of chemical biology.

[59]  Simon C Watkins,et al.  Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. , 2002, American journal of respiratory cell and molecular biology.

[60]  D. Yoon,et al.  HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing , 2002, Experimental & Molecular Medicine.

[61]  I. Zuhorn,et al.  Lipoplex-mediated Transfection of Mammalian Cells Occurs through the Cholesterol-dependent Clathrin-mediated Pathway of Endocytosis* , 2002, The Journal of Biological Chemistry.

[62]  B. Pitt,et al.  Complex Roles of CpG in Liposomal Delivery of DNA and Oligonucleotides , 2002, Bioscience reports.

[63]  Y. Barenholz,et al.  Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation. , 2001, Biochimica et biophysica acta.

[64]  Leaf Huang,et al.  Nonviral vectors in the new millennium: delivery barriers in gene transfer. , 2001, Human gene therapy.

[65]  P. Cullis,et al.  Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. , 2001, Biochimica et biophysica acta.

[66]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[67]  M. Hope,et al.  Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells. , 2000, Antisense & nucleic acid drug development.

[68]  M. Gilchrist,et al.  Aerosolized Syk Antisense Suppresses Syk Expression, Mediator Release from Macrophages, and Pulmonary Inflammation1 , 2000, The Journal of Immunology.

[69]  I. Lebedeva,et al.  Antisense Oligonucleotides in Cancer , 2000, BioDrugs.

[70]  B. Engelhardt,et al.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[71]  D. Stuart,et al.  A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. , 2000, Biochimica et biophysica acta.

[72]  B. Calabretta,et al.  Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.

[73]  A. Tari,et al.  Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. , 1999, The Journal of pharmacology and experimental therapeutics.

[74]  S. Stibitz,et al.  Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. , 1999, Journal of immunology.

[75]  G. Gregoriadis,et al.  Biodistribution, stability, and antiviral efficacy of liposome‐entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection , 1998, Hepatology.

[76]  T Ochi,et al.  A comparison of in vivo gene delivery methods for antisense therapy in ligament healing , 1998, Gene Therapy.

[77]  T Salditt,et al.  An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. , 1998, Science.

[78]  M. Tormo,et al.  Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. , 1998, Leukemia & lymphoma.

[79]  J. Rossi,et al.  Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. , 1998, Biochimica et biophysica acta.

[80]  M. Fresta,et al.  Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. , 1998, Journal of pharmaceutical sciences.

[81]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[82]  V. Soldatenkov,et al.  Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer , 1997, Gene Therapy.

[83]  J. Fitchett,et al.  Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[84]  T. Abe,et al.  [Antisense nucleic acid therapy of influenza virus]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[85]  Joachim O. Rädler,et al.  Structure of DNA-Cationic Liposome Complexes: DNA Intercalation in Multilamellar Membranes in Distinct Interhelical Packing Regimes , 1997, Science.

[86]  D. Ma,et al.  Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. , 1996, Leukemia research.

[87]  F. Szoka,et al.  Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[88]  F. Szoka,et al.  Intracellular Distribution and Mechanism of Delivery of Oligonucleotides Mediated by Cationic Lipids , 1996, Pharmaceutical Research.

[89]  Leaf Huang,et al.  Potentiation of cationic liposome-mediated gene delivery by polycations. , 1996, Biochemistry.

[90]  M. Wainberg,et al.  Antiviral activity and protection of cells against human immunodeficiency virus type-1 using an antisense oligodeoxyribonucleotide phosphorothioate complementary to the 5'-LTR region of the viral genome. , 1995, Gene.

[91]  R. Akhurst,et al.  Liposome-medicated gene transfer and expression via the skin. , 1995, Human molecular genetics.

[92]  G. Zon,et al.  Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). , 1995, Toxicology letters.

[93]  J. Wright,et al.  Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate. , 1995, Leukemia.

[94]  Joseph Zabner,et al.  Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid (*) , 1995, The Journal of Biological Chemistry.

[95]  G. Karlsson,et al.  Complexes between cationic liposomes and DNA visualized by cryo-TEM. , 1995, Biochimica et biophysica acta.

[96]  M. Wainberg,et al.  Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome , 1995, Journal of virology.

[97]  Leaf Huang,et al.  New structures in complex formation between DNA and cationic liposomes visualized by freeze—fracture electron microscopy , 1994, FEBS letters.

[98]  C. Sirlin,et al.  Gene transfer with a series of lipophilic DNA-binding molecules. , 1994, Bioconjugate chemistry.

[99]  F. Holsboer,et al.  Antisense oligodeoxynucleotides for in vivo targeting of corticotropin-releasing hormone mRNA: comparison of phosphorothioate and 3'-inverted probe performance. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[100]  K. Karikó,et al.  Lipofectin‐aided cell delivery of ribozyme targeted to human urokinase receptor mRNA , 1994, FEBS letters.

[101]  A. Tanswell,et al.  Antisense oligodeoxynucleotides targeting PDGF-B mRNA inhibit cell proliferation during embryonic rat lung development. , 1994, Development.

[102]  T. Allen.  Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.

[103]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[104]  L. Huang,et al.  DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.

[105]  S. Capaccioli,et al.  Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. , 1993, Biochemical and biophysical research communications.

[106]  R. Ghirlando,et al.  Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. , 1993, Biochemistry.

[107]  G. Degols,et al.  Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes. , 1993, Antiviral research.

[108]  S. Epstein,et al.  Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[109]  A. Dritschilo,et al.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. , 1992, Nucleic acids research.

[110]  A. Dritschilo,et al.  Liposomal Delivery of Antisense Oligodeoxynucleotides. , 1992 .

[111]  C. Bennett,et al.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.

[112]  P. Couvreur,et al.  Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. , 1992, Biochemical and biophysical research communications.

[113]  S. Krawczyk,et al.  Triple helix formation inhibits transcription elongation in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[114]  L. Huang,et al.  A novel cationic liposome reagent for efficient transfection of mammalian cells. , 1991, Biochemical and biophysical research communications.

[115]  L. Leserman,et al.  Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. , 1990, The Journal of biological chemistry.

[116]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[117]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[118]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[119]  D. Friend,et al.  Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles , 1983, Cell.

[120]  K. Jacobson,et al.  Use of lectins and polyethylene glycol for fusion of glycolipid-containing liposomes with eukaryotic cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[121]  H. Klenk,et al.  Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. , 1980, Virology.

[122]  F. Szoka,et al.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[123]  W. A. Hagins,et al.  Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. , 1977, Science.

[124]  N. Minakawa,et al.  The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[125]  J. Byrd,et al.  Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. , 2009, Molecular pharmaceutics.

[126]  R. Kole,et al.  RNA modulation, repair and remodeling by splice switching oligonucleotides. , 2004, Acta biochimica Polonica.

[127]  R. Kole,et al.  Modulation of alternative splicing by antisense oligonucleotides. , 2003, Progress in molecular and subcellular biology.

[128]  M. Hope,et al.  Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. , 2000, Methods in enzymology.

[129]  B. Calabretta,et al.  Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. , 2000, Journal of the National Cancer Institute.

[130]  T. Abe,et al.  Inhibition of influenza virus replication by phosphorothioate and liposomally endocapsulated oligonucleotides. , 1998, Nucleosides & nucleotides.

[131]  T. Jarvis,et al.  Optimization of lipid-mediated ribozyme delivery to cells in culture. , 1997, Methods in molecular biology.

[132]  G. Zon,et al.  Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. , 1993, Antisense research and development.

[133]  A. Dritschilo,et al.  Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. , 1992, Annals of the New York Academy of Sciences.

[134]  F. Szoka,et al.  Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.

[135]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.